Shannon James Samuel
SEC insider (Form 3/4/5 filer). CIK 0001485417. Director at Xilio Therapeutics, Inc. (XLO) and 2 other issuers. 9 reported Form 4/5 transactions since Sep 2024; latest on Jun 11, 2026. Located in WALTHAM, MA.
Companies Shannon James Samuel has filed insider reports for
- Xilio Therapeutics, Inc. (XLO): Director
- MANNKIND CORP (MNKD): Director
- ProQR Therapeutics N.V. (PRQR): Director
Shannon James Samuel
CIK: 0001485417
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jun 11, 2026XLO
Xilio Therapeutics, Inc.
AwardDirectStock Option (right to buy)
5K shares- - May 20, 2026MNKD
MANNKIND CORP
AwardDirectRestricted Stock Unit
82.8K shares- - May 20, 2026MNKD
MANNKIND CORP
AwardDirectRestricted Stock Unit
16.6K shares- - Mar 26, 2026XLO
Xilio Therapeutics, Inc.
PurchaseDirect5K shares at avg. $8.79$44K - Mar 1, 2026MNKD
MANNKIND CORP
AwardDirect12K shares at avg. $3.27$39K - Jun 17, 2025XLO
Xilio Therapeutics, Inc.
PurchaseDirect25K shares at avg. $0.69$17K - Jun 16, 2025XLO
Xilio Therapeutics, Inc.
PurchaseDirect45K shares at avg. $0.69$31K - Jun 11, 2025XLO
Xilio Therapeutics, Inc.
AwardDirectStock Option (right to buy)
31K shares- - May 14, 2025MNKD
MANNKIND CORP
AwardDirectRestricted Stock Unit
52.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 11, 2026 |  XLO Xilio Therapeutics, Inc. | Award Stock Option (right to buy) | 5,000 | - | - | Direct |
| May 20, 2026 |  MNKD MANNKIND CORP | Award Restricted Stock Unit | 82,781 | - | - | Direct |
| May 20, 2026 | MNKD MANNKIND CORP | Award Restricted Stock Unit | 16,556 | - | - | Direct |
| Mar 26, 2026 | XLO Xilio Therapeutics, Inc. | Purchase | 5,000 | $8.79 | $43,950 | Direct |
| Mar 1, 2026 | MNKD MANNKIND CORP | Award | 12,000 | $3.27 | $39,240 | Direct |
| Jun 17, 2025 | XLO Xilio Therapeutics, Inc. | Purchase | 25,000 | $0.69 | $17,215 | Direct |
| Jun 16, 2025 | XLO Xilio Therapeutics, Inc. | Purchase | 45,000 | $0.69 | $30,870 | Direct |
| Jun 11, 2025 | XLO Xilio Therapeutics, Inc. | Award Stock Option (right to buy) | 31,000 | - | - | Direct |
| May 14, 2025 | MNKD MANNKIND CORP | Award Restricted Stock Unit | 52,854 | - | - | Direct |
1-9 of 9 transactions